GET THE APP

Chemopotenetiation by Low-Dose-Fractionated Radiation Therapy
..

Nuclear Medicine & Radiation Therapy

ISSN: 2155-9619

Open Access

Chemopotenetiation by Low-Dose-Fractionated Radiation Therapy


International Conference on Nuclear Medicine & Radiation Therapy

July 14-15, 2016 Cologne, Germany

France Carrier

University of Maryland, USA

Scientific Tracks Abstracts: J Nucl Med Radiat Ther

Abstract :

The emerging concept of chemopotentiation by Low Dose Fractionated Radiation Therapy (LDFRT) is not fully understood but builds on the phenomenon of low-dose hyper-radiosensitivity (HRS). This new paradigm allows the use of full dose systemic chemotherapy safely in combination with LDFRT, where the low-dose radiation sensitizes the tumor to subsequent chemotherapy. Using a RT2 PCR Profiler Array, we identified Dual Oxidase 2 (DUOX2), an enzyme functioning in the production of hydrogen peroxide, as a major mediator of chemopotentiation by LDFRT. Down regulation of DUOX2 increased radioresistance at every radiation doses tested. In addition, our data indicate that Reactive Oxygen Species increase up to 3.5 fold in cells exposed to LDFRT and a modified regimen of Docetaxel, Cisplatin, and 5├ó┬?┬?-fluorouracil (mDCF). Furthermore, inhibition of NADPH oxidase abrogated the killing efficiency of this combined regimen in human gastric cancer cells. Taken together, these data suggest that chemopotentiation by LDFRT may be due, at least in part, to increased ROS production (DUOX2) without upregulation of the DNA repair machinery. These data thus provide a rationale for further explorations of potential clinical applications of LDFRT, such as in Whole abdominal radiotherapy, as a chemopotentiator for advanced and metastatic gastric cancers.

Biography :

France Carrier is a tenured Associate Professor in the Department of Radiation Oncology at the University of Maryland, School of Medicine in Baltimore, MD, USA. Her laboratory focuses on basic and translational cancer research with emphasis on molecular events underlying cancer progression and most specifically DNA damage responses. She is particularly interested in the activation of RNA binding proteins, HDACIs and Low Dose Fractionated Radiation Therapy. She is a National Institutes Health funded investigator and has published more than 60 peer reviewed articles and book chapters. Her papers have been cited more than 6,500 times.

Eamil: FCarrier@som.umaryland.edu

Google Scholar citation report
Citations: 636

Nuclear Medicine & Radiation Therapy received 636 citations as per Google Scholar report

Nuclear Medicine & Radiation Therapy peer review process verified at publons

Indexed In

 
arrow_upward arrow_upward